enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...
Stay updated with breaking news from Ryan Daws. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead...
Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer remains on track with interim data anticipated in mid-2024 Closed a $200 million oversubscribed private...
Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with...
”There is a lot of anxiety among CFOs,” says Nick Leopard, founder and CEO of Accordion.
“Finance and operations go hand in hand,” said Cramer, formerly of Parade, Inc. and Bath & Body Works.